Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota

• Published in: Theranostics 2021, Vol.11 (17), p.8570-8586
• Main Authors: Tong, Lingjun, Hao, Haining, Zhang, Zhe, Lv, Youyou, Liang, Xi, Liu, Qiqi, Liu, Tongjie, Gong, Pimin, Zhang, Lanwei, Cao, Fangfang, Pastorin, Giorgia, Lee, Chuen Neng, Chen, Xiaoyuan, Wang, Jiong-Wei, Yi, Huaxi
• Format: Article
• Language: English
• Subjects: Acids; Animals; Biotechnology; China; Colitis - drug therapy; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - metabolism; Colon - drug effects; Cytokines; Cytokines - metabolism; Digestive system; Disease Models, Animal; Extracellular vesicles; Extracellular Vesicles - genetics; Extracellular Vesicles - metabolism; Extracellular Vesicles - physiology; Gastrointestinal Microbiome - drug effects; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory diseases; Intestinal Mucosa - metabolism; Intestines - metabolism; Laboratory animals; Male; Mice; Mice, Inbred C57BL; Microbiota; MicroRNAs; Milk; Milk - metabolism; NF-kappa B - metabolism; Proteins; RAW 264.7 Cells; Research Paper; RNA, Ribosomal, 16S - genetics; Signal Transduction; T-Lymphocytes, Regulatory - metabolism; Th17 Cells - metabolism
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/THNO.62046

Bovine milk constitutes an essential part of human diet, especially for children, due to its enrichment of various nutrients. We recently developed an effective protocol for the isolation of extracellular vesicles from milk (mEVs) and discovered that mEVs contained large amounts of immune-active proteins and modulated the gut immunity and microbiota in healthy mice. Here, we aimed to explore the therapeutic effects of mEVs on inflammatory bowel disease. MicroRNAs and protein content in mEVs were analyzed by RNA sequencing and proteomics, respectively, followed by functional annotation. Ulcerative colitis (UC) was induced by feeding mice with dextran sulfate sodium. Intestinal immune cell populations were phenotyped by flow cytometry, and the gut microbiota was analyzed 16S rRNA sequencing. We showed that abundant proteins and microRNAs in mEVs were involved in the regulation of immune and inflammatory pathways and that oral administration of mEVs prevented colon shortening, reduced intestinal epithelium disruption, inhibited infiltration of inflammatory cells and tissue fibrosis in a mouse UC model. Mechanistically, mEVs attenuated inflammatory response inhibiting TLR4-NF-κB signaling pathway and NLRP3 inflammasome activation. Furthermore, mEVs were able to correct cytokine production disorder and restore the balance between T helper type 17 (Th17) cells and interleukin-10 Foxp3 regulatory T (Treg) cells in the inflamed colon. The disturbed gut microbiota in UC was also partially recovered upon treatment with mEVs. The correlation between the gut microbiota and cytokines suggests that mEVs may modulate intestinal immunity influencing the gut microbiota. These findings reveal that mEVs alleviate colitis by regulating intestinal immune homeostasis inhibiting TLR4-NF-κB and NLRP3 signaling pathways, restoring Treg/Th17 cell balance, and reshaping the gut microbiota.